ArticleFrontiers in immunology2026
Efficacy of immune checkpoint inhibitors combined with different chemotherapy in recurrent pancreatic cancer: a retrospective study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Recurrence affects 65%-75% of pancreatic cancer (PC) patient post-resection. Established salvage strategies for recurrent PC are lacking, and systemic chemotherapy offers limited survival benefits. This study aimed to evaluate the efficacy and safety of immune checkpoint inhibitors (ICIs) combined with different chemotherapy in patients with recurrent PC, specifically FOLFIRINOX (a combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and Gemcitabine plus Nab-paclitaxel (AG).Materials and methods: We retrospectively screened 201 patients with recurrent PC between March 2016 and September 2022. A total of 113 eligible patients were enrolled, including 23 in the chemotherapy combined with ICIs group and 90 in the chemotherapy-only group. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS). Subgroup analyses were performed based on chemotherapy regimens (FOLFIRINOX vs. AG). Results: In the overall cohort, the chemotherapy combined with ICIs group demonstrated a trend toward improved survival compared to the chemotherapy group. Subgroup analysis revealed that among patients receiving the FOLFIRINOX regimen, the addition of ICIs was significantly associated with improved OS (median OS: not reached vs. 14.9 months; HR = 0.266 [95% CI: 0.077-0.919]; log-rank Conclusion: Combining ICIs with FOLFIRINOX-based chemotherapy was significantly associated with improved OS in patients with recurrent PC with an acceptable safety profile. This combination strategy represents a promising therapeutic option for recurrent PC, particularly when paired with the FOLFIRINOX backbone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.